Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. IBM
10. KNX

Go back to Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
(NASDAQ: PLRZ) Delayed: 15.31 +0.92 (6.39%)
Previous Close $14.39    52 Week High $ 
Open $14.39    52 Week Low $ 
Day High $15.31    P/E N/A 
Day Low $13.59    EPS $ 
Volume 92,925